 |
|
Association Between the Use of β-Adrenergic Receptor Agents and the Development of Venous Leg Ulcers
DavidJ. Margolis, MD, PhD;
Ole Hoffstad, MA;
R. Rivkah Isseroff, MD
Arch Dermatol. 2007;143(10):1275-1280.
Objective To explore an association between the use of β-adrenergic receptor agonists or antagonists and the onset of venous leg ulcers (VLUs).
Design Retrospective cohort study.
Setting Ambulatory setting of general practice in the United Kingdom.
Patients Patients followed by participating physicians.
Main Outcome Measure Onset of VLU.
Results A total of 414 887 patients registered in the General Practice Research Database met our study criteria for eligibility. Of these individuals, 62 886 were exposed to a β-adrenergic receptor agonist and 54 861 were exposed to a β-adrenergic receptor antagonist (6620 used both β-adrenergic receptor antagonists and agonists). Of those exposed to a β-adrenergic receptor agonist, 15.5% developed a VLU, whereas 18.4% of those who were not exposed developed a VLU. Of those exposed to a β-adrenergic receptor antagonist, 18.2% developed a VLU, whereas 19.9% of those not exposed developed a VLU. The odds ratio (OR) of association between β-adrenergic receptor antagonist and VLUs was 1.02 (95% confidence interval [CI], 0.99-1.04); for the association between β-adrenergic receptor agonist and VLUs, 0.84 (95% CI, 0.82-0.86). The fully adjusted ORs were 1.04 (95% CI, 0.98-1.11) and 0.44 (95% CI, 0.42-0.45), respectively. Furthermore, using propensity score models, we were able to confirm the association for β-adrenergic receptor agonist users. In addition, β-adrenergic receptor antagonist users in many of the propensity score quintiles were also protected from developing VLUs.
Conclusions A protective association between β-adrenergic receptor agonists and perhaps β-adrenergic receptor antagonists and VLUs exists. There is strong laboratory evidence to support these epidemiologic findings. The evidence in this study should not be used as a rationale for treatment of VLUs with β-adrenergic receptor agents but should be compelling for the consideration of a randomized clinical trial.
Author Affiliations: Department of Dermatology (Dr Margolis) and Center for Epidemiology and Biostatistics (Dr Margolis and Mr Hoffstad), University of Pennsylvania School of Medicine, Philadelphia; Department of Dermatology, University of California, Davis (Dr Isseroff); and Dermatology Service, Department of Veterans Affairs, Northern California Health Care System, Mather (Dr Isseroff).
RELATED ARTICLE
Wound Healing
Robert S. Kirsner
Arch Dermatol. 2007;143(10):1318-1319.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Wound Healing
Kirsner
Arch Dermatol 2007;143:1318-1319.
FULL TEXT
|
